Our principal, Ms. Pauli Wong, was invited to speak at the Hong Kong Life Sciences Society (HKLSS) Summer Internship Program 2024 on “Unlocking Patent Law: Exploring IP Career Paths” in July. This program aims to cultivate young talents to drive life sciences innovation. In addition, she participated in the discussion session titled “Evolving Landscape – Investment Outlook for the Healthcare and Life Sciences Sectors” alongside Mr. Tian Tan, the Vice President of NF Trinity.

Pauli shared her career journey becoming a patent attorney at Eagle IP, from an HKU biotech graduate and a scientist with CK Life Sciences. She provided an introduction to intellectual property, particularly patents, and life sciences challenges we are facing, and how to pursue a career path in patent law. By sharing her own experiences, Pauli offered valuable insights and guidance to the aspiring interns to appreciate the importance of IP and consider a career path in patent law.

Our Past Events

Jennifer Che has been Recognized in IAM Strategy 300 Global Leaders 2026

26 November 2025

Jennifer Che has been Recognized as IAM Global Leaders 2026

4 November 2025

Eagle IP is Coming to San Francisco and Washington DC!

15 October 2025

Jennifer Che has been listed on the IAM Strategy 300

15 August 2025

Eagle IP Recognized as Top Tier Firm (Tier 1) for Patent Prosecution in IP Stars 2025 Patent Firms Ranking List

3 July 2025

Dr. Jacqueline Lui, Ms. Pauli Wong, and Mr. Eddie Ho Named Patent Stars by ManagingIP

13 June 2025

Recommended Insights

Hong Kong Launches New Original Grant Patent System

17 December 2019
Hong Kong will be launching a new patent system on December 19, 2019 that includes key changes, most notably the introduction of an original grant patent system. This new patent system includes both the Patents (Amendment) Ordinance 2016 and the Patents (General) (Amendment) Rules 2019. Currently, there are two types of patent applications available in […]
Read more >

CHINA DIVISIONAL PATENT STRATEGY: Recent Judgment Narrows What Constitutes “Different Inventions” for Divisionals

6 December 2021
In China, patents applicants take advantage of a commonly-used divisional filing strategy to achieve a fine-tuned balance between protection scope and protection period (if used properly). Patent applicants (especially foreign applicants) widely welcome this well-established strategy, and up until now, have used it with much success. In fact, we recommend this strategy and have even […]
Read more >

First ever Invalidation decision on an RNAi Invention patent in China

4 December 2023
Decision on Examination of Request for Invalidation (No. 58530) In one of China’s Top 10 Patent Re-examination / Invalidation cases of 2022, an invalidation decision on a patent claiming Hepatitis B Virus (HBV) RNAi compositions (No. 58530) by the Patent Re-examination Board (the “Board”) sheds light on the standard for post filing data for rejections […]
Read more >

What Kind of Damage Awards Can You Get in China?

16 June 2022
Is it worth filing for a patent in China? What kind of damage awards can you get? Pharma companies care more about injunction than damage awards, since it’s quite unlikely that any damage award can compensate for the large amounts of money that may be lost for patent infringement. Chinese courts often issue injunctions in […]
Read more >
Top crossarrow-right